This molecule strongly inhibited KDM4A in in vitro assays with an IC50 of 24.37 and 10.1 μM, and in breast cancer cells increased the levels of H3K9me3 and H3K36me3, specific targets of KDM4A, already after 24 h of treatment at 10 μM. Here, KDM4A is linked to breast carcinoma.